105 related articles for article (PubMed ID: 1825123)
1. Activation and in vitro expansion of tumor-reactive T lymphocytes from lymph nodes draining human primary breast cancers.
Hoover SK; Frank JL; McCrady C; McKinnon JG; Bear HD
J Surg Oncol; 1991 Feb; 46(2):117-24. PubMed ID: 1825123
[TBL] [Abstract][Full Text] [Related]
2. Activation of CD8+ murine T cells from tumor-draining lymph nodes by phorbol dibutyrate plus calcium ionophore.
Tuttle TM; Inge TH; McCrady CM; Bethke KP; Bear HD
J Immunother (1991); 1992 Jul; 12(1):32-40. PubMed ID: 1386251
[TBL] [Abstract][Full Text] [Related]
3. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
4. Alteration of human lymphokine-activated killer cell activity by manipulation of protein kinase C and cytosolic Ca2+.
McCrady CW; Li F; Grant AJ; Merchant RE; Carchman RA
Cancer Res; 1988 Feb; 48(3):635-40. PubMed ID: 3257170
[TBL] [Abstract][Full Text] [Related]
5. Activation and expansion of cytotoxic T lymphocytes from tumor-draining lymph nodes.
McKinnon JG; Hoover SK; Inge TH; Bear HD
Cancer Immunol Immunother; 1990; 32(1):38-44. PubMed ID: 2126983
[TBL] [Abstract][Full Text] [Related]
6. Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1.
Tuttle TM; Inge TH; Bethke KP; McCrady CW; Pettit GR; Bear HD
Cancer Res; 1992 Feb; 52(3):548-53. PubMed ID: 1732041
[TBL] [Abstract][Full Text] [Related]
7. Expansion and tumour specific cytokine secretion of bryostatin-activated T-cells from cryopreserved axillary lymph nodes of breast cancer patients.
Lind DS; Tuttle TM; Bethke KP; Frank JL; McCrady CW; Bear HD
Surg Oncol; 1993 Oct; 2(5):273-82. PubMed ID: 8305969
[TBL] [Abstract][Full Text] [Related]
8. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor.
Itoh K; Platsoucas CD; Balch CM
J Exp Med; 1988 Oct; 168(4):1419-41. PubMed ID: 3262710
[TBL] [Abstract][Full Text] [Related]
9. Bryostatin 1 activates T cells that have antitumor activity.
Tuttle TM; Inge TH; Wirt CP; Frank JL; McCrady CM; Bear HD
J Immunother (1991); 1992 Aug; 12(2):75-81. PubMed ID: 1504056
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of CD4+ and CD8+ T cells in tumor tissues, lymph nodes and the peripheral blood from patients with breast cancer.
Riazi Rad F; Ajdary S; Omranipour R; Alimohammadian MH; Hassan ZM
Iran Biomed J; 2015; 19(1):35-44. PubMed ID: 25605488
[TBL] [Abstract][Full Text] [Related]
11. In vitro expansion of tumor-specific, HLA-restricted human CD8+ cytolytic T lymphocytes.
Nakashima M; Watanabe T; Koprowski H; Schuchter L; Steplewski Z
Cell Immunol; 1994 Apr; 155(1):53-61. PubMed ID: 7513262
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.
Baldwin NG; Rice CD; Tuttle TM; Bear HD; Hirsch JI; Merchant RE
J Neurooncol; 1997 Mar; 32(1):19-28. PubMed ID: 9049859
[TBL] [Abstract][Full Text] [Related]
13. Characterization of cells from invaded lymph nodes in patients with solid tumors. Lymphokine requirement for tumor-specific lymphoproliferative response.
Cozzolino F; Torcia M; Carossino AM; Giordani R; Selli C; Talini G; Reali E; Novelli A; Pistoia V; Ferrarini M
J Exp Med; 1987 Aug; 166(2):303-18. PubMed ID: 2955070
[TBL] [Abstract][Full Text] [Related]
14. Phorbol dibutyrate plus ionomycin improves the generation of cytotoxic T cells from draining lymph nodes of patients with advanced head and neck cancer.
McGrath PC; Hamby LS; Freeman JW
Am J Surg; 1992 Dec; 164(6):610-4. PubMed ID: 1463110
[TBL] [Abstract][Full Text] [Related]
15. gamma-Interferon plays a key role in T-cell-induced tumor regression.
Tuttle TM; McCrady CW; Inge TH; Salour M; Bear HD
Cancer Res; 1993 Feb; 53(4):833-9. PubMed ID: 8428364
[TBL] [Abstract][Full Text] [Related]
16. Proliferation, phenotype, and cytotoxicity of human lymphocytes isolated from lymph nodes invaded by melanoma cells.
Nakashima M; Janiszewska M; Steplewski Z; Watanabe T; Schuchter L; Koprowski H
Hybridoma; 1994 Jun; 13(3):241-6. PubMed ID: 7927369
[TBL] [Abstract][Full Text] [Related]
17. Enrichment in tumor-reactive CD8+ T-lymphocytes by positive selection from the blood and lymph nodes of patients with head and neck cancer.
Letessier EM; Heo DS; Okarma T; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1991 Aug; 51(15):3891-9. PubMed ID: 1677310
[TBL] [Abstract][Full Text] [Related]
18. Induction of tumoricidal activity and alterations of growth by interleukin-2 and manipulation of protein kinase C and cytosolic calcium in childhood acute lymphocytic leukemia cells.
Massey GV; McCrady CW; Dunn NL; Russell EC; Carchman RA
Leukemia; 1989 Aug; 3(8):602-10. PubMed ID: 2787455
[TBL] [Abstract][Full Text] [Related]
19. Evidence for the existence of distinct heterogeneity among the peripheral CD4-CD8- T cells from MRL-lpr/lpr mice based on the expression of the J11d marker, activation requirements, and functional properties.
Kakkanaiah VN; Nagarkatti M; Nagarkatti PS
Cell Immunol; 1990 May; 127(2):442-57. PubMed ID: 2139366
[TBL] [Abstract][Full Text] [Related]
20. Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. II. Cytokine production and in vivo efficacy of glioma-sensitized lymphocytes.
Rice CD; Baldwin NG; Biron RT; Bear HD; Merchant RE
J Neurooncol; 1997 Mar; 32(1):29-38. PubMed ID: 9049860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
